ClinicalRegeneron reports encouraging phase 2 results for baloncibart in...

Regeneron reports encouraging phase 2 results for baloncibart in a crucial trial for nervous system disorders and eyes

-

Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome (POTS), teeing the biotech up to start a potentially pivotal trial in the autonomic nervous system disorder in the first half of 2027.

Understanding POTS and Regeneron’s Approach

The heart rate of POTS patients increases abnormally when they get up from sitting or lying down. Some symptoms, such as palpitations and dizziness, happen when patients stand up and lessen when they sit or lie down. However, chronic symptoms such as fatigue, exercise intolerance, cognitive problems, GI symptoms, and chronic pain are also common with POTS.

Regeneron believed that inhibiting NPR1 would help reduce the symptoms by increasing the amount of blood in the circulatory system. In the Phase 2 Pinnacle trial, the biotech tested this theory once again by taking 82 patients with POTS and randomly administering them two doses of the anti-NPR1 antibody baloncibart or placebo.

Phase 2 Pinnacle Trial Results

Trial primary endpoint met: At Day 8, baloncibart recipients experienced a 450 mg dose of a single dose of baloncibart, which resulted in a 11.4 beats per minute (bpm) difference between their change in heart rate from lying down to standing position compared with those taking placebo. The difference between the arms was 7.4 bpm on Day 29. The 150 mg baloncibart dose was superior to placebo on Day 8, but had a diminishing effect by Day 29.

On the biotech’s third-quarter earnings call late last month, George Yancopoulos, Regeneron’s chief scientific officer, spoke about the phase 2 study. Improvements that “appear to be associated with durable restoration of intravascular volume” inform Regeneron’s belief that baloncibart “could be a game-changing treatment for a debilitating disease with significant unmet need,” Yancopoulos said.

Symptom Improvements and Safety Profile

Patients’ performance on physical functioning and activities of daily living also improved on the 450 mg dose of the drug compared to placebo at Day 29, and symptoms related to standing did, too. No real benefits were seen with the 150 mg dose over the placebo.

On Day 8, Regeneron disclosed that the biomarker changes were consistent with what was expected after blood volume reduction with baloncibart. Mean standing systolic blood pressure rose with both doses, by 8.7 mmHg to 118.8 mmHg on Day 29 in the 450 mg group.

There were more treatment-emergent adverse events (TEAEs) in the baloncibart arm than in the placebo arm, with 67.9% of patients with the 450-mg dose of baloncibart experiencing these events versus 48.1% in the placebo arm. The majority of the TEAEs were mild or moderate, and none resulted in a treatment discontinuation.

Next Steps and Unmet Market Need

Based on the data, Regeneron plans to start a phase 3 clinical trial in the first half of next year. The study, which may prove key to regulatory clearance, could indicate that Regeneron’s claim is reached by 500,000 to several million people in the U.S. POTS is diagnosed more often in women and has been traditionally underdiagnosed.

POTS has not been treated with FDA-approved medications, and there are few industry-sponsored clinical development programs. Argenx and CSL Behring conducted clinical trials in COVID-19 patients with POTS, but there are currently no active clinical trials.

Regeneron Reports Encouraging Phase 2 Results for Baloncibart

Regeneron Pharmaceuticals has reported encouraging Phase 2 clinical trial results for baloncibart, an investigational antibody being developed for postural orthostatic tachycardia syndrome (POTS). The findings suggest that the experimental treatment may help reduce abnormal increases in heart rate when patients move from lying down to standing.

The results come from the Phase 2 PINNACLE trial, which evaluated the safety and potential effectiveness of baloncibart in adults living with POTS. The company presented the findings at the American Autonomic Society’s 37th International Symposium on the Autonomic Nervous System in November 2026.

Latest news

Top 10 Risks Associated With Pharmaceutical Raw Material Sourcing

Executive Summary Pharmaceutical raw material sourcing directly influences product quality, manufacturing continuity, regulatory compliance, and commercial performance. Active pharmaceutical ingredients...

Bristol Myers Squibb Combines Research and Development Under Cristian Massacesi

Bristol Myers Squibb (BMS) will consolidate its research and development operations into a single organization under the leadership of...

Pfizer and Starna Therapeutics Sign an Exclusive Licensing Contract for Autoimmune Conditions

Pfizer Inc. announced that it has entered into an exclusive collaboration with Starna Therapeutics, a biotechnology company focused on...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you